Frazier Life Sciences Management
Latest statistics and disclosures from Frazier Life Sciences Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NAMS, KRYS, MIRM, HLVX, ALPN, and represent 38.61% of Frazier Life Sciences Management's stock portfolio.
- Added to shares of these 10 stocks: Cg Oncology (+$34M), ORIC (+$28M), PEPG (+$22M), BBIO (+$21M), SLNO (+$18M), Adverum Biotechnologies (+$15M), PBYI (+$15M), GPCR (+$13M), APLT (+$13M), ALLO (+$13M).
- Started 7 new stock positions in ALLO, PBYI, APLT, Cg Oncology, Adverum Biotechnologies, Metagenomi, PEPG.
- Reduced shares in these 10 stocks: MDGL (-$16M), DYN (-$16M), CRNX (-$14M), ETNB (-$12M), APGE (-$11M), Theseus Pharmaceuticals (-$8.6M), RYTM (-$7.8M), COGT (-$7.1M), ACAD, Mirati Therapeutics.
- Sold out of its positions in APGE, CRNX, DYN, MDGL, Mirati Therapeutics, Theseus Pharmaceuticals.
- Frazier Life Sciences Management was a net buyer of stock by $123M.
- Frazier Life Sciences Management has $2.4B in assets under management (AUM), dropping by 26.71%.
- Central Index Key (CIK): 0001892134
Tip: Access up to 7 years of quarterly data
Positions held by Frazier Life Sciences Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Frazier Life Sciences Management
Frazier Life Sciences Management holds 50 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 12.2 | $289M | 12M | 23.65 |
|
|
| Krystal Biotech (KRYS) | 7.4 | $176M | 989k | 177.93 |
|
|
| Mirum Pharmaceuticals (MIRM) | 6.9 | $163M | 6.5M | 25.12 |
|
|
| Hillevax (HLVX) | 6.9 | $163M | 9.8M | 16.63 |
|
|
| Alpine Immune Sciences (ALPN) | 5.2 | $124M | 3.1M | 39.64 |
|
|
| Phathom Pharmaceuticals (PHAT) | 4.5 | $107M | 10M | 10.62 |
|
|
| Bridgebio Pharma (BBIO) | 4.5 | $106M | +25% | 3.4M | 30.92 |
|
| Rhythm Pharmaceuticals (RYTM) | 4.0 | $95M | -7% | 2.2M | 43.33 |
|
| Arcutis Biotherapeutics (ARQT) | 3.7 | $87M | 8.8M | 9.91 |
|
|
| Vaxcyte (PCVX) | 3.3 | $78M | -2% | 1.1M | 68.31 |
|
| Tarsus Pharmaceuticals (TARS) | 2.7 | $65M | 1.8M | 36.35 |
|
|
| Edgewise Therapeutics (EWTX) | 2.5 | $60M | +23% | 3.3M | 18.24 |
|
| Oric Pharmaceuticals (ORIC) | 2.4 | $57M | +93% | 4.1M | 13.75 |
|
| Apellis Pharmaceuticals (APLS) | 2.2 | $52M | 885k | 58.78 |
|
|
| Disc Medicine (IRON) | 2.1 | $49M | 785k | 62.26 |
|
|
| Verona Pharma Sponsored Ads (VRNA) | 2.0 | $49M | 3.0M | 16.09 |
|
|
| Kalvista Pharmaceuticals (KALV) | 1.8 | $44M | 3.7M | 11.86 |
|
|
| Rocket Pharmaceuticals (RCKT) | 1.8 | $42M | +2% | 1.6M | 26.94 |
|
| Soleno Therapeutics (SLNO) | 1.6 | $38M | +88% | 876k | 42.80 |
|
| Macrogenics (MGNX) | 1.5 | $36M | +2% | 2.5M | 14.72 |
|
| Aerovate Therapeutics (AVTE) | 1.5 | $36M | 1.2M | 29.57 |
|
|
| Cg Oncology | 1.4 | $34M | NEW | 770k | 43.90 |
|
| Merus N V (MRUS) | 1.4 | $34M | 747k | 45.03 |
|
|
| Revolution Medicines (RVMD) | 1.4 | $32M | 998k | 32.23 |
|
|
| Autolus Therapeutics Spon Ads (AUTL) | 1.2 | $30M | +23% | 4.6M | 6.38 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 1.1 | $27M | +98% | 629k | 42.86 |
|
| Trevi Therapeutics (TRVI) | 1.1 | $26M | 7.4M | 3.45 |
|
|
| Silence Therapeutics Ads (SLN) | 1.0 | $25M | +30% | 1.1M | 21.60 |
|
| Deciphera Pharmaceuticals (DCPH) | 1.0 | $23M | +42% | 1.5M | 15.73 |
|
| Pepgen (PEPG) | 0.9 | $22M | NEW | 1.5M | 14.70 |
|
| Anaptysbio Inc Common (ANAB) | 0.9 | $20M | 900k | 22.52 |
|
|
| Savara (SVRA) | 0.8 | $20M | 4.0M | 4.98 |
|
|
| Cerevel Therapeutics Hldng I (CERE) | 0.7 | $17M | 393k | 42.27 |
|
|
| Agios Pharmaceuticals (AGIO) | 0.6 | $15M | 523k | 29.24 |
|
|
| Adverum Biotechnologies | 0.6 | $15M | NEW | 1.1M | 14.14 |
|
| Puma Biotechnology (PBYI) | 0.6 | $15M | NEW | 2.8M | 5.30 |
|
| Tyra Biosciences (TYRA) | 0.6 | $14M | -18% | 832k | 16.40 |
|
| Applied Therapeutics (APLT) | 0.6 | $13M | NEW | 2.0M | 6.80 |
|
| Allogene Therapeutics (ALLO) | 0.5 | $13M | NEW | 2.9M | 4.47 |
|
| Arvinas Ord (ARVN) | 0.5 | $12M | 285k | 41.28 |
|
|
| 89bio (ETNB) | 0.5 | $12M | -50% | 1.0M | 11.64 |
|
| ACADIA Pharmaceuticals (ACAD) | 0.4 | $8.7M | -35% | 470k | 18.49 |
|
| Cogent Biosciences (COGT) | 0.3 | $6.3M | -53% | 937k | 6.72 |
|
| Intellia Therapeutics (NTLA) | 0.2 | $5.6M | 204k | 27.51 |
|
|
| Newamsterdam Pharma Company *w Exp 11/22/202 (NAMSW) | 0.2 | $5.5M | 500k | 11.04 |
|
|
| An2 Therapeutics (ANTX) | 0.2 | $4.5M | 1.4M | 3.25 |
|
|
| Metagenomi | 0.1 | $2.9M | NEW | 279k | 10.55 |
|
| Gritstone Oncology Ord (GRTS) | 0.1 | $2.6M | 1.0M | 2.57 |
|
|
| Bluebird Bio (BLUE) | 0.1 | $2.2M | 1.7M | 1.28 |
|
|
| Aclaris Therapeutics (ACRS) | 0.0 | $328k | 264k | 1.24 |
|
Past Filings by Frazier Life Sciences Management
SEC 13F filings are viewable for Frazier Life Sciences Management going back to 2022
- Frazier Life Sciences Management 2024 Q1 filed May 15, 2024
- Frazier Life Sciences Management 2023 Q4 filed Feb. 14, 2024
- Frazier Life Sciences Management 2023 Q3 filed Nov. 14, 2023
- Frazier Life Sciences Management 2023 Q2 filed Aug. 14, 2023
- Frazier Life Sciences Management 2023 Q1 filed May 15, 2023
- Frazier Life Sciences Management 2022 Q4 restated filed Feb. 7, 2023
- Frazier Life Sciences Management 2022 Q4 filed Feb. 3, 2023
- Frazier Life Sciences Management 2022 Q3 filed Nov. 14, 2022
- Frazier Life Sciences Management 2022 Q2 filed Aug. 10, 2022
- Frazier Life Sciences Management 2022 Q1 filed May 16, 2022